154 related articles for article (PubMed ID: 34443335)
21. A Quick Route to Multiple Highly Potent SARS-CoV-2 Main Protease Inhibitors*.
Yang KS; Ma XR; Ma Y; Alugubelli YR; Scott DA; Vatansever EC; Drelich AK; Sankaran B; Geng ZZ; Blankenship LR; Ward HE; Sheng YJ; Hsu JC; Kratch KC; Zhao B; Hayatshahi HS; Liu J; Li P; Fierke CA; Tseng CK; Xu S; Liu WR
ChemMedChem; 2021 Mar; 16(6):942-948. PubMed ID: 33283984
[TBL] [Abstract][Full Text] [Related]
22. Structure-Activity Relationships of Benzamides and Isoindolines Designed as SARS-CoV Protease Inhibitors Effective against SARS-CoV-2.
Welker A; Kersten C; Müller C; Madhugiri R; Zimmer C; Müller P; Zimmermann R; Hammerschmidt S; Maus H; Ziebuhr J; Sotriffer C; Schirmeister T
ChemMedChem; 2021 Jan; 16(2):340-354. PubMed ID: 32930481
[TBL] [Abstract][Full Text] [Related]
23. Integrated bioinformatics-cheminformatics approach toward locating pseudo-potential antiviral marine alkaloids against SARS-CoV-2-Mpro.
Swain SS; Singh SR; Sahoo A; Panda PK; Hussain T; Pati S
Proteins; 2022 Sep; 90(9):1617-1633. PubMed ID: 35384056
[TBL] [Abstract][Full Text] [Related]
24. Aziridine analogs of [[trans-(epoxysuccinyl)-L-leucyl]amino]-4-guanidinobutane (E-64) as inhibitors of cysteine proteases.
Martichonok V; Plouffe C; Storer AC; Ménard R; Jones JB
J Med Chem; 1995 Aug; 38(16):3078-85. PubMed ID: 7636871
[TBL] [Abstract][Full Text] [Related]
25. 2-Pyridone natural products as inhibitors of SARS-CoV-2 main protease.
Forrestall KL; Burley DE; Cash MK; Pottie IR; Darvesh S
Chem Biol Interact; 2021 Feb; 335():109348. PubMed ID: 33278462
[TBL] [Abstract][Full Text] [Related]
26. Chalcones isolated from Angelica keiskei inhibit cysteine proteases of SARS-CoV.
Park JY; Ko JA; Kim DW; Kim YM; Kwon HJ; Jeong HJ; Kim CY; Park KH; Lee WS; Ryu YB
J Enzyme Inhib Med Chem; 2016; 31(1):23-30. PubMed ID: 25683083
[TBL] [Abstract][Full Text] [Related]
27. Simultaneous Inhibition of SARS-CoV-2 Entry Pathways by Cyclosporine.
Prasad K; Ahamad S; Kanipakam H; Gupta D; Kumar V
ACS Chem Neurosci; 2021 Mar; 12(5):930-944. PubMed ID: 33606519
[TBL] [Abstract][Full Text] [Related]
28. Some Flavolignans as Potent Sars-Cov-2 Inhibitors
Cetin A
Curr Comput Aided Drug Des; 2022; 18(5):337-346. PubMed ID: 35975852
[TBL] [Abstract][Full Text] [Related]
29. Mycotoxins from Fusarium proliferatum: new inhibitors of papain-like cysteine proteases.
Silva TL; Toffano L; Fernandes JB; das Graças Fernandes da Silva MF; de Sousa LRF; Vieira PC
Braz J Microbiol; 2020 Sep; 51(3):1169-1175. PubMed ID: 32189177
[TBL] [Abstract][Full Text] [Related]
30. In Silico Identification of Potential Natural Product Inhibitors of Human Proteases Key to SARS-CoV-2 Infection.
Vivek-Ananth RP; Rana A; Rajan N; Biswal HS; Samal A
Molecules; 2020 Aug; 25(17):. PubMed ID: 32842606
[TBL] [Abstract][Full Text] [Related]
31. Analysis of non-peptidic compounds as potential malarial inhibitors against Plasmodial cysteine proteases via integrated virtual screening workflow.
Musyoka TM; Kanzi AM; Lobb KA; Tastan Bishop Ö
J Biomol Struct Dyn; 2016 Oct; 34(10):2084-101. PubMed ID: 26471975
[TBL] [Abstract][Full Text] [Related]
32. Fluorine Atoms on C
Chaves OA; Rodrigues-Santos CE; Echevarria Á; Sacramento CQ; Fintelman-Rodrigues N; Temerozo JR; Castro-Faria-Neto HC; Souza TMLE
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142848
[TBL] [Abstract][Full Text] [Related]
33. Binding of SARS-CoV Covalent Non-Covalent Inhibitors to the SARS-CoV-2 Papain-Like Protease and Ovarian Tumor Domain Deubiquitinases.
Sivakumar D; Stein M
Biomolecules; 2021 May; 11(6):. PubMed ID: 34071582
[TBL] [Abstract][Full Text] [Related]
34. Identification of potential plant-based inhibitor against viral proteases of SARS-CoV-2 through molecular docking, MM-PBSA binding energy calculations and molecular dynamics simulation.
Gogoi B; Chowdhury P; Goswami N; Gogoi N; Naiya T; Chetia P; Mahanta S; Chetia D; Tanti B; Borah P; Handique PJ
Mol Divers; 2021 Aug; 25(3):1963-1977. PubMed ID: 33856591
[TBL] [Abstract][Full Text] [Related]
35. Can Cysteine Protease Cross-Class Inhibitors Achieve Selectivity?
Cianni L; Feldmann CW; Gilberg E; Gütschow M; Juliano L; Leitão A; Bajorath J; Montanari CA
J Med Chem; 2019 Dec; 62(23):10497-10525. PubMed ID: 31361135
[TBL] [Abstract][Full Text] [Related]
36. Dipeptide-derived nitriles containing additional electrophilic sites: potentially irreversible inhibitors of cysteine proteases.
Löser R; Gütschow M
J Enzyme Inhib Med Chem; 2009 Dec; 24(6):1245-52. PubMed ID: 19912058
[TBL] [Abstract][Full Text] [Related]
37. Structure-activity relationship (SAR) and molecular dynamics study of withaferin-A fragment derivatives as potential therapeutic lead against main protease (M
Ghosh A; Chakraborty M; Chandra A; Alam MP
J Mol Model; 2021 Feb; 27(3):97. PubMed ID: 33641023
[TBL] [Abstract][Full Text] [Related]
38. Cytotoxicity of Thioalkaloid-Enriched
Muduli S; Golan-Goldhirsh A; Gopas J; Danilenko M
Pharmaceuticals (Basel); 2022 Mar; 15(4):. PubMed ID: 35455407
[TBL] [Abstract][Full Text] [Related]
39. Identification of novel human USP2 inhibitor and its putative role in treatment of COVID-19 by inhibiting SARS-CoV-2 papain-like (PLpro) protease.
Mirza MU; Ahmad S; Abdullah I; Froeyen M
Comput Biol Chem; 2020 Dec; 89():107376. PubMed ID: 32979815
[TBL] [Abstract][Full Text] [Related]
40. In Silico Drug Repositioning to Target the SARS-CoV-2 Main Protease as Covalent Inhibitors Employing a Combined Structure-Based Virtual Screening Strategy of Pharmacophore Models and Covalent Docking.
Vázquez-Mendoza LH; Mendoza-Figueroa HL; García-Vázquez JB; Correa-Basurto J; García-Machorro J
Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409348
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
